Morning Watchlist: Sunday Edition
A quick note from Behind the Markets
Sunday is for the risks that don't fit in a trading headline.
Fertilizer shortages take months to reach food prices. Regional-bank exposure looks manageable until deposits leave. A fast-fashion IPO priced at a quarter of its private valuation tells you what public investors will no longer pay for growth.
These are slow-moving pressures — exactly the kind Wall Street ignores until they become obvious. Two of today's four sections end with a company worth owning. The other two end with a reason not to reach.
1) The Next Food Inflation Shock Is Already in the Fertilizer Aisle
A combination of a super El Niño, higher energy costs, fertilizer constraints tied to the Middle East conflict, and grain-shipping disruptions is raising the risk of another food-inflation wave. The FAO has warned that higher crude, lost fertilizer supply, and tight diesel availability could push food prices higher later this year.
The diesel crack spread hit a record $102.20 a barrel on August 17 — the first time in history above $100, against a normal range of $15 to $25. Diesel is not an abstraction to a farmer. It runs the tractor, the irrigation pump, the grain truck, and the rail line. When distillate margins quadruple, every step between a seed and a supermarket shelf gets more expensive at once, and fertilizer production — which is energy-intensive by nature — gets squeezed from both ends.
The market notices food inflation at the checkout. Investors should watch the input chain first: nitrogen and phosphate producers, rail and port logistics, farm equipment, irrigation, crop protection, and distributors with working-capital discipline. And note the sequencing — farmers cannot always pass higher fertilizer costs through immediately, which squeezes farm income before it reaches the consumer. The pain lands on the producer before it lands on the shopper.
The buffer is real, too. Crop inventories are healthy in several categories, yields keep improving, and major exporters can cushion a disruption. Buffers are not immunity, but they do mean this is a risk to monitor rather than a fire to run toward.
No name today. We looked closely at CF Industries previously and reached an uncomfortable conclusion that still holds: it passes almost every quality test for a nitrogen producer — lowest-cost gas, strong balance sheet, real buybacks — and it was trading above the analyst consensus after a 55% run. The time to own the low-cost producer is when the spot-price narrative is boring, not when the FAO is issuing warnings. That was true two weeks ago and the FAO headline doesn't change it.
Bottom line: Food inflation starts with farm inputs long before it reaches the checkout line. Follow efficiency, distribution, and logistics — and remember that the input squeeze hits the farmer's income statement first.
2) Regional Banks Still Have a Commercial-Real-Estate Blind Spot
A Federal Reserve note published this month finds that regional banks carry far greater commercial-real-estate exposure than the largest banks, and are more vulnerable to shocks in low-cost deposits and local property markets. That's a map of where refinancing costs and deposit costs meet.
We have the surrounding numbers from our own work this month: CMBS delinquency around 7.5% with special servicing near 11%, office delinquency at record highs above 12%, roughly $76.6 billion of CMBS hard maturities landing in 2026, and — the number that matters most — more than half of recent private-credit default events resolved through maturity extensions rather than payments. The market is buying time.
The easy trade is to buy a bank after a selloff. The better discipline is to underwrite the loan book: which properties secure the loans, whether rents are growing or merely being extended, how much collateral value assumes a full office recovery, and whether the bank can replace maturing deposits without giving away its margin. A cheap price-to-book ratio can be a warning that book value is optimistic.
So look at the layer that gets paid while the workout happens.
The Stock: Houlihan Lokey (NYSE: HLI)
Houlihan Lokey is the premier restructuring advisory franchise on Wall Street — the firm creditors and distressed borrowers call when a loan cannot be refinanced on its original terms. It also runs a large mid-market M&A business and a valuation practice, which matters because those three lines tend to work at different points in a cycle. Restructuring earns when things break; corporate finance earns when they don't.
Management's own read on the pipeline is the interesting part. On the July call, CEO Scott Adelson said restructuring activity remains strong and is expected to stay elevated through fiscal 2027, citing volatility in energy markets, dislocation in private credit, and stress in software — with the CFO noting the firm's technology advisory investments could position it for a wave of software restructurings over the next two to three years given how many highly leveraged businesses sit in that sector. That is management describing, in its own words, the same private-credit stress we've been tracking since August 7.
First-quarter fiscal 2027 results, reported July 29, were poor. Revenue fell 15.5% to $511 million. Adjusted earnings dropped to $1.35 from $2.14. Corporate Finance revenue fell 24% on lower average fees across 127 closed deals, hurt by extended transaction timelines amid Middle East instability and software-sector disruption. The stock fell nearly 10% to around $132.
Most importantly for the thesis: Financial Restructuring revenue fell 8% to $119 million, with closed transactions down 34% — from 35 to 23. In the prior full fiscal year, restructuring revenue declined 3%. The CRE and private-credit stress is visible in the data everywhere except in the revenue line of the firm that would monetize it. One genuine bright spot inside that: average transaction fees on closed restructuring deals rose, meaning fewer but larger mandates. And Financial and Valuation Advisory grew 13% on 1,042 fee events.
The bear case is specific and well-argued. Wells Fargo initiated coverage at Underweight with a $149 target, arguing that consensus restructuring estimates are too high if the economy achieves a soft landing — and preferring pure-play M&A recovery names given monetary easing. UBS trimmed to $160 with a Neutral. Goldman is at $168. The compensation ratio ran 64.3%, and the firm is absorbing acquisitions (Intrepid Financial Partners in energy, plus Waller Helms). Management called the quarter "a temporary disruption and not a fundamental resetting of our outlook" — which is what management always says, and which the next two prints will test.
Verdict: the right business model for a slow-moving credit problem, bought after a 10% drop, with the uncomfortable fact that the restructuring wave everyone expects has not yet arrived in the revenue. If the maturity wall converts into mandates, this is early. If the extensions keep working, it's dead money with a dividend.
Bottom line: Regional-bank risk is a funding-and-collateral problem, not just a rate problem. Underwrite deposits and property cash flow before the stock chart — and consider whether you'd rather own the workout than the loan book.
3) Shein's IPO Discount Is a Warning About Growth at Any Price
Shein is reportedly targeting a valuation near $25 billion for a Hong Kong listing — far below the roughly $100 billion mark from an earlier private share sale.
A lower valuation does not make a business cheap. It shows that public investors demand a different price than private ones for fast growth attached to regulatory risk, supply-chain exposure, and uncertain durability. Private marks can stay high long after public buyers start asking about cash generation, customer acquisition cost, compliance, and repeat purchase — because private marks are set by negotiation among a handful of parties, and public prices are set by anyone willing to sell.
The lesson generalizes well beyond one fashion company, and it's worth a checklist you can reuse on any consumer IPO:
Is growth organic or promotion-driven? Orders can rise while margin is given away.
Are returns rising? In apparel, the return rate is the tell — it converts revenue into cost.
Can the company prove supplier compliance? For this business model, that's an existential regulatory question, not a footnote.
Does the model work when shipping, tariffs, and customer-acquisition costs normalize? Several fast-fashion economics depend on de minimis import treatment and cheap logistics — both of which are policy variables, not laws of nature.
There's a connection worth making to Saturday's issue, too. We noted that Target's comparable sales grew on traffic up 3.6% with average ticket flat — customers arriving more often and spending the same. A retailer built on discount-driven acquisition faces the sharper version of that problem: revenue is not a moat if the customer only arrives for the discount.
Bottom line: A down-round IPO is a market signal about the cost of growth. Judge the repeat purchase, not the order count.
4) Medtech Consolidation Is Pointing to the Picks and Shovels
Two deals in the space of a week make the case.
On August 3, KKR agreed to take Integer Holdings private for about $5.7 billion — $127 per share in cash, taking out one of the largest medical-device contract development and manufacturing organizations in the world. On August 10, Teledyne agreed to acquire Varex Imaging for $18.90 per share, roughly $1.1 billion including net debt, adding X-ray sources, digital detectors, and imaging software used in medical diagnostics, non-destructive inspection, and security screening.
These sit inside a pattern, not a coincidence. Over the past year private equity has also taken out Avanos Medical for $1.27 billion, and Blackstone and TPG agreed to acquire Hologic for $18.3 billion. KKR — with $796 billion under management — made Integer its largest healthcare deal since 2018. As a KeyBanc analyst put it, private buyers are "realizing the value of public" medtech.
Notice what they're buying. Not blockbuster drugs. Components, sensors, imaging, and regulated manufacturing — businesses with long qualification cycles, recurring replacement demand, and customers who cannot switch suppliers overnight without re-validating a finished device with regulators. The value is in reliability and certification, which is pricing power that doesn't require a consumer brand.
One detail worth pausing on. Integer's $127 price is widely described as a 52% premium — but that's measured against the April 29 close, the day before the company announced a strategic review. Against the 30-day average through July 31 it's about 29%, and against the actual prior close it's roughly 4.8%, because the shares had already jumped nearly 20% on a press report. As always: the premium belongs to whoever owned it before the process began.
Which is the argument for owning the supplier before the buyer arrives.
The Stock: UFP Technologies (NASDAQ: UFPT)
UFP Technologies is the closest listed comparable to what KKR just bought: a contract development and manufacturing organization for single-use and single-patient medical devices, sterile packaging, and highly engineered custom products. Its components go into robotic-assisted surgery, patient beds and safe-patient handling, infection control, cardiovascular, orthopedics and spine, and wound care. It is a "vital link in the medical device supply chain" for most of the world's top device manufacturers.
The second quarter, reported August 3 (event risk cleared), set records across the board. Net sales rose 15.1% to $174.0 million against roughly $159.4 million expected — a 9% beat. Adjusted earnings of $2.92 beat the $2.56 consensus by 14%. Net income rose 21.4% to $20.9 million. Adjusted EBITDA of $36.4 million came in 11.5% above expectations at a 20.9% margin. Organic growth was 12%. Over five years the company has compounded revenue at roughly 27.5% annually, partly through a disciplined serial-acquisition strategy — it recently added UNIPEC and TPI for film and thermoplastic molding capability, and opened two new Dominican Republic facilities to support robotic surgery and safe patient handling.
Now the other side, and there's a fair amount of it.
The stock jumped about 24% on that report and is up roughly 49% in 2026, trading near 30 times free cash flow. You would be buying immediately after a very large move, and one analyst who likes the business acknowledged it "isn't as cheap as it previously was."
The largest product line was flat. Robotic surgery drapes — the biggest segment — showed essentially no growth in the quarter; the 15% came from everywhere else. That's diversification working, but it isn't the growth engine most people assume they're buying.
Growth is decelerating from the five-year trend, running about 23% annually over two years against 27.5% over five. First-quarter sales grew only 4.1%, with non-medical sales down 15% as the company deliberately concentrates on medtech. And management provided no 2026 guidance, which leaves the Street modeling in the dark.
Verdict: the right business in the right lane, with a clean set of quarterly numbers and an entry price that already reflects them. If you want it, want it on a pullback — the acquirers in this sector have been paying for exactly these characteristics, and they wait for their price too.
Before You Go
Slow risks make the best research, because they give you time to be right before the market agrees.
Fertilizer moves before food — and a record diesel margin is already in the input chain. Deposits move before bank losses — and the restructuring advisers say the pipeline is building even though the revenue hasn't arrived. Public valuations reset before private narratives — Shein's mark fell 75% before a single share traded. And qualified medtech suppliers compound quietly until a buyer pays 52% for one on a Monday morning.
But notice what today also says about timing. The restructuring firm's revenue is down, not up. The medtech supplier already jumped 24%. The fertilizer producer is above its target price. Being early and being wrong feel identical for a long time, and the difference is whether the cash flow eventually shows up.
That's the job: find the pressure point early, identify who monetizes it, and refuse to pay for a story that hasn't earned its cash flow yet.
Found this helpful? Share it with others.
Written by Behind the Markets